Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation, part I: pentoxifylline.

Susan Givens Bell1

  • 1NICU, All Children's Hospital, St Petersburg, Florida, USA.

Neonatal Network : NN
|August 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enteral Iron Supplementation.

Neonatal network : NN·2026
Same author

Ondansetron: A Novel Treatment to Reduce the Severity of Neonatal Opioid Withdrawal Syndrome?

Neonatal network : NN·2025
Same author

Second-Line Medications for Neonatal Opioid Withdrawal Syndrome/Neonatal Abstinence Syndrome.

Neonatal network : NN·2025
Same author

The Evidence-Based Practice Process Steps 4, 5, and 6: Integration, Evaluation, and Dissemination.

Neonatal network : NN·2024
Same author

Step 3: Critical Appraisal of Evidence-Expert Opinion.

Neonatal network : NN·2024
Same author

Step 3: Critically Appraising Evidence: Case-Control Studies.

Neonatal network : NN·2023

Pentoxifylline (PTXF) shows promise as an add-on treatment for neonatal sepsis, with no observed adverse effects. Further large clinical trials are needed to confirm its efficacy and role in treating sepsis in newborns.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Immunomodulation

Background:

  • Neonatal sepsis remains a significant cause of mortality and morbidity.
  • Current antibiotic therapies have limitations, necessitating novel adjunct treatments.
  • Immunomodulatory agents are being explored to improve outcomes in neonatal sepsis.

Purpose of the Study:

  • To evaluate the potential role of pentoxifylline (PTXF) as an adjunct therapy for neonatal sepsis.
  • To review existing literature on PTXF's safety and efficacy in neonates.
  • To identify areas for future research in PTXF for neonatal sepsis treatment.

Main Methods:

  • Literature review of studies investigating PTXF in neonatal sepsis.
  • Analysis of reported adverse effects and clinical outcomes.

Related Experiment Videos

  • Identification of key comorbidities and outcomes for future trial consideration.

    • Main Results:

    • PTXF appears promising as an adjunct to antibiotic therapy in neonatal sepsis.
    • No adverse effects were reported in the reviewed literature.
    • Existing studies are limited, necessitating further investigation.

    Conclusions:

    • PTXF demonstrates potential as a safe adjunct therapy for neonatal sepsis.
    • Large randomized clinical trials are required to validate PTXF's efficacy.
    • Future studies should assess PTXF alongside other immunomodulatory agents and consider key comorbidities.